A Phase 1, Randomized, Placebo Controlled Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA LAMP Vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

Trial Profile

A Phase 1, Randomized, Placebo Controlled Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA LAMP Vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs ARA LAMP vax (Primary) ; ARA LAMP vax (Primary)
  • Indications Peanut hypersensitivity
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 13 Apr 2017 Planned End Date changed from 1 May 2018 to 10 Jul 2018.
    • 13 Apr 2017 Planned primary completion date changed from 1 May 2018 to 10 Jul 2018.
    • 18 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top